QL1706 with olaparib for advanced HER2-negative breast cancer with HRD
Part of Cancer clinical trials.
This trial tests a combination of two drugs (QL1706 and olaparib) for people with advanced breast cancer that is HER2-negative and has a specific DNA repair problem called HRD. It's for those who have already tried 2 to 4 previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have a good performance status (ECOG 0 or 1).
- Your breast cancer is HER2-negative and advanced (locally advanced or metastatic), and it is either hormone-receptor positive or triple-negative.
- You have received 2 to 4 prior treatments for advanced disease.
- Your tumor has a positive test for homologous recombination deficiency (HRD) or you have a harmful BRCA gene mutation.
- You have at least one measurable tumor, adequate organ function, and a life expectancy of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two antibody drugs (trastuzumab and pertuzumab) plus a targeted pill (olaparib) given before surgery to treat elderly women with HER2-positive breast cancer. The goal is to see if this approach helps shrink tumors or eliminate them entirely before surgery.
This trial tests a combination of two drugs, QL1706 (an immunotherapy) and olaparib (a targeted therapy), for people with a specific type of advanced breast cancer called triple-negative that has a DNA repair problem (HRD). It may be an option if you've had 1 or 2 prior treatments but haven't tried similar drugs before.
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
This trial tests a new drug (QL1706) combined with hormone therapy for breast cancer that did not shrink enough with initial chemotherapy. The goal is to see if this combination can improve treatment response before surgery.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
Hear when a new Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.